IRIS Accounts Production v24.2.0.383 12349768 director 1.1.23 31.12.23 31.12.23 20/9/2024 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh123497682022-12-31123497682023-12-31123497682023-01-012023-12-31123497682021-12-31123497682022-01-012022-12-31123497682022-12-3112349768ns15:EnglandWales2023-01-012023-12-3112349768ns14:PoundSterling2023-01-012023-12-3112349768ns10:Director12023-01-012023-12-3112349768ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3112349768ns10:SmallEntities2023-01-012023-12-3112349768ns10:Audited2023-01-012023-12-3112349768ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3112349768ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3112349768ns10:FullAccounts2023-01-012023-12-3112349768ns10:RegisteredOffice2023-01-012023-12-3112349768ns5:CurrentFinancialInstruments2023-12-3112349768ns5:CurrentFinancialInstruments2022-12-3112349768ns5:ShareCapital2023-12-3112349768ns5:ShareCapital2022-12-3112349768ns5:FurtherSpecificReserve2ComponentTotalEquity2023-12-3112349768ns5:FurtherSpecificReserve2ComponentTotalEquity2022-12-3112349768ns5:RetainedEarningsAccumulatedLosses2023-12-3112349768ns5:RetainedEarningsAccumulatedLosses2022-12-3112349768ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3112349768ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 12349768 (England and Wales)










FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

FOR

SGI-DNA LIMITED

SGI-DNA LIMITED (REGISTERED NUMBER: 12349768)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


SGI-DNA LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2023







Director: Mr E Esser





Registered office: Suite 2 First Floor
10 Temple Back
Bristol
United Kingdom
BS1 6FL





Registered number: 12349768 (England and Wales)





Auditors: Mark Arber Limited
Statutory Auditors
71-75 Shelton Street
Covent Garden
London
WC2H 9JQ

SGI-DNA LIMITED (REGISTERED NUMBER: 12349768)

BALANCE SHEET
31 DECEMBER 2023

31/12/23 31/12/22
Notes £    £   
CURRENT ASSETS
Debtors 4 204,001 300,296
Cash at bank 160,045 128,693
364,046 428,989
CREDITORS
Amounts falling due within one year 5 (136,714 ) (250,074 )
NET CURRENT ASSETS 227,332 178,915
TOTAL ASSETS LESS CURRENT
LIABILITIES

227,332

178,915

CAPITAL AND RESERVES
Called up share capital 100 100
Other reserves 88,077 63,357
Retained earnings 139,155 115,458
SHAREHOLDERS' FUNDS 227,332 178,915

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 18 September 2024 and were signed by:





Mr E Esser - Director


SGI-DNA LIMITED (REGISTERED NUMBER: 12349768)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1. STATUTORY INFORMATION

SGI-DNA Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Company’s functional and presentational currency is pounds sterling (GBP) and the financial statements have been rounded to the nearest pound (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

These accounts have been drawn up on the going concern basis. The company is dependent upon the support of its parent company, and only customer, in order to meet its working capital requirements. The parent company has suffered recuring losses from operations that raise substantial doubt about its ability to continue as a going concern. This in turn creates uncertainty over the ability of SGI-DNA Limited to continue as a going concern. The directors of the parent are confident that they will secure financing to enable the group to continue as a going concern for a period exceeding twelve months from the date these financial statements were approved by the board. No adjustments have been made in these accounts which might result from that uncertainty.

Going concern
These financial statements have been drawn up on the going concern basis. The company is dependent upon the support of its parent company, and only customer, in order to meet its working capital requirements.

The parent company has provided assurances that it intends this support to continue for a period that exceeds twelve months from the date of approval of these financial statements. However, since inception, the group has incurred cumulative operating losses and negative cash flows from operations. These operating losses and negative cash flows have been financed principally from the issuance of equity securities and debt. In the future, such capital may not be available in sufficient amounts, on terms acceptable to the Group, or at all. Risks to which the Group is exposed include uncertainties related to the ability to achieve revenue-generating products; current and potential competitors with greater financial, technological, production, and marketing resources; dependence on key management personnel; and raising additional capital, as needed. As such there is a material uncertainty that the group may continue as a going concern.

These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty and the withdrawal of financial support.

Turnover
Revenue is recognised to the extent that is probable that the economic benefit will flow to the Company and the revenue can be reliable measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts and rebates.The following criteria must also be met before revenue is recognised.

Revenue represents amounts charged to the Company's parent an agreement for sales and marketing support provided.. Revenue is recognised when chargeable costs are incurred.

Financial instruments
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are initially recognised at transaction price.


SGI-DNA LIMITED (REGISTERED NUMBER: 12349768)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2022 - 10 ) .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/12/23 31/12/22
£    £   
Amounts owed by group undertakings 202,125 296,595
Deferred tax asset 383 2,208
Prepayments 1,493 1,493
204,001 300,296

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/12/23 31/12/22
£    £   
Trade creditors 2,319 523
Tax 10,401 34,942
Social security and other taxes 10,949 49,183
Accrued expenses 113,045 165,426
136,714 250,074

6. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Mark Arber (Senior Statutory Auditor)
for and on behalf of Mark Arber Limited

SGI-DNA LIMITED (REGISTERED NUMBER: 12349768)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023

7. PENSIONS COMMITMENTS

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £53,010 (2022 - £61,846). Contributions totalling £3,733 (2022 - £8,479) were payable to the fund at the balance sheet date and are included in creditors.

8. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

9. ULTIMATE CONTROLLING PARTY

Telesis Bio Inc. is the ultimate parent company at the balance sheet.

The largest and smallest group in which the results of the company are consolidated is that by Telesis Bio Inc., a privately incorporated in the United States of America, with its principal place of business at 10431 Wateridge Circle, Suite 150, San Diego, CA 92121.

10. SHARE BASED PAYMENTS DISCLOSURE EXEMPTION

The Company has taken the exemption provided in FRS 102 Section 1.12D not to disclose details of share-based payment arrangements concerning equity instruments of another group entity.

11. SECURED LIABILITIES

There is a fixed and floating charge over the assets of the company in respect of borrowings made by the parent company Telesis Bio Inc.